WaveMan
WaveMan · Company
LFCR · Lifecore Biomedical, Inc. De
> Search tickers & screens ⌘K
LIVE
← All companies

LFCR Lifecore Biomedical, Inc. DE (LFCR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001005286
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Lifecore Biomedical, Inc. DE insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for LIFECORE BIOMEDICAL, INC. DE in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
English Aron R.
SELL
2025-05-28 SEC
150,419
$1.1M
-6.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 27, 2025.
  • The trade is 56.9% of the 264,180 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Insider English Aron R. sold about $1.1M of LFCR on May 28, 2025; 2 other insiders sold within 30 days.
English Aron R.
SELL
2025-05-28 SECtraded 2025-05-27
1,139,504
$7.4M
-6.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 23, 2025.
  • The trade is 274.8% of the 414,599 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Insider English Aron R. sold about $7.4M of LFCR on May 27, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
English Aron R.
SELL
2025-05-28 SECtraded 2025-05-23
96,137
$648.9K
-6.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.2% of the 1,554,103 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Insider English Aron R. sold about $648.9K of LFCR on May 23, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
22NW Fund GP, LLC
SELL
2025-05-16 SECtraded 2025-05-13
12,334
$86.3K
-4.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 12, 2025.
  • The trade is 0.7% of the 1,650,240 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Insider 22NW Fund GP, LLC sold about $86.3K of LFCR on May 13, 2025; 2 other insiders sold within 30 days.
22NW Fund GP, LLC
SELL
2025-05-12 SEC
45,698
$321.3K
-7.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 9, 2025.
  • The trade is 2.7% of the 1,662,574 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Insider 22NW Fund GP, LLC sold about $321.3K of LFCR on May 12, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 14 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+0.5% year over year
below 52% of Pharma & Biotech
Margin
-30.0% net margin
more than 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.8% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
more than 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LFCR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.4%12M
-46%-21%+4%+30%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LFCR: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in LFCR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LFCR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Paul Josephs
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.1M
$831.1K
$3.1M
-44%
+10%
2021
$956.8K
$711.5K
$687.6K
-18%
-18%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LFCR financials

Revenue growth
+0.5%
XBRL, annual
Net margin
-30.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$381.6M
market value at close 2026-10-26 on 2026-07-29 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-052024-052023-052023-02
Revenue$128.9M$128.3M$103.3Mn/a
Gross profit$40.3M$41.9M$28.0Mn/a
Operating income-$17.2M-$8.8M-$21.8Mn/a
Net income-$38.7M$12.0M-$99.6Mn/a
EPS (diluted)-1.270.33-3.32n/a
Operating cash flow-$206.0K$257.0K-$17.4Mn/a
Cash$8.3M$8.5M$19.1M$3.0M
Long-term debt$130.4M$100.8M$84.3M$98.9M
SEC XBRL, fiscal years, as known on 2026-10-28

LFCR Stock Sonar score 2/7 axes

Find similar shapesCompare
Growth
48
Inputs
  • Revenue growth, YoY+0.5% · 48 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
17
Inputs
  • Short interest, % of float+12.8% · 31 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+61.2% · 3 pct, sector of 511
5 not measured: Profitability, Financial health, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies